Warrenton

Researchers are evaluating the efficacy and safety of ORKA-002 in adults with moderate-to-severe plaque psoriasis. This multicenter, randomized, double-blinded, placebo-controlled study aims to find the best induction dosing regimen of ORKA-002. Approximately 160 adult participants with this skin condition will take part in the Phase 2 trial. Participants will be randomly assigned to receive one of three different induction dosing regimens of ORKA-002 or a placebo. Both ORKA-002 and placebo are given by subcutaneous injection. The study includes three periods Screening, Induction, and Post-treatment Follow-up. During the study, participants will undergo assessments including evaluations of skin severity using PASI and IGA scores. Researchers will monitor treatment-emergent adverse events through Week 48. The primary outcome is the proportion of participants achieving complete clearance of psoriasis at Week 16. The total participation time includes screening, treatment, and follow-up periods to assess safety and treatment response.

Researchers are evaluating the real-world clinical impact of the Galleri4, a blood-based multi-cancer early detection MCED test, in a Medicare population aged 50 years and older. This multi-center prospective cohort study aims to assess the tests safety and performance alongside usual care, enrolling participants representative of Medicare beneficiaries. The study is observational and compares outcomes between those receiving the Galleri test plus usual care and those receiving usual care alone. Participants in the Galleri-tested arm will have blood collected for the MCED test with results returned to guide further evaluation. The comparator group consists of Medicare beneficiaries receiving usual care without the Galleri test. Both groups will be observed over a period of up to 3 years to evaluate cancer incidence and diagnostic outcomes. Throughout the study, researchers will monitor the incidence of stage IV cancers, the number and types of invasive procedures following test results, adherence to recommended cancer screening, and healthcare resource use related to cancer diagnostics. Safety and test performance will be tracked in the Galleri-tested group. Participation involves routine clinical visits and data collection for up to 3 years, with no interventions withheld for either group.